Zhigen Pharmaceutical

Zhigen Pharmaceutical is a private Shanghai-based biopharmaceutical company focused on innovative small-molecule drugs and difficult-to-develop generic products. The company was founded in 2021 and operates from Zhangjiang Pharma Valley in Pudong, where it has built internal capabilities in medicinal chemistry, synthesis, and formulation. Its disclosed pipeline includes ZG-001, an antidepressant that received Chinese clinical trial clearance, and ZG-002, an autoimmune disease candidate that has completed Phase 1 testing with disclosed relevance to moderate-to-severe plaque psoriasis. Patent activity suggests additional discovery work in TYK2 inhibitors, aminoketone CNS compounds, and biased opioid receptor ligands. The company has raised venture financing to advance its lead programs and expand its pipeline.